問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Linkou Chang Gung Medical Foundation

List

2449Cases

2018-12-01 - 2024-12-31

Phase III

Completed
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB OR PLACEBO IN COMBINATION WITH NEOADJUVANT DOXORUBICIN + CYCLOPHOSPHAMIDE FOLLOWED BY PACLITAXEL + TRASTUZUMAB + PERTUZUMAB IN EARLY HER2-POSITIVE BREAST CANCER

  • Condition/Disease

    EARLY HER2-POSITIVE BREAST CANCER

  • Test Drug

    Atezolizumab

Participate Sites
5Sites

Terminated4Sites

王惠暢
China Medical University Hospital

Division of General Surgery

2018-07-01 - 2023-06-02

Phase III

Completed
A PHASE III, RANDOMIZED, MULTICENTER, OPEN-LABEL, TWO-ARM STUDY TO EVALUATE THE PHARMACOKINETICS, EFFICACY, AND SAFETY OF SUBCUTANEOUS ADMINISTRATION OF THE FIXED-DOSE COMBINATION OF PERTUZUMAB AND TRASTUZUMAB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH HER2-POSITIVE EARLY BREAST CANCER

  • Condition/Disease

    HER2-POSITIVE EARLY BREAST CANCER

  • Test Drug

    Pertuzumab and Trastuzumab FDC, Perjeta, Herceptin, Cyclophosphamide, Paclitaxel, Docetaxel, Doxorubincin

Participate Sites
4Sites

Terminated3Sites

曾令民
Taipei Veterans General Hospital

Division of General Surgery

陳訓徹
Linkou Chang Gung Medical Foundation

2023-03-06 - 2030-12-31

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2025-10-15 - 2032-12-31

Phase III

Not yet recruiting
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early-Stage Parkinson's Disease

  • Condition/Disease

    Parkinson's Disease

  • Test Drug

    injections

Participate Sites
5Sites

Recruiting5Sites

2025-09-15 - 2030-12-31

Phase III

Active
A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP EFFICACY AND SAFETY STUDY OF TRONTINEMAB IN PARTICIPANTS WITH EARLY SYMPTOMATIC ALZHEIMER’S DISEASE (MCI TO MILD DEMENTIA DUE TO AD)

  • Condition/Disease

    EARLY SYMPTOMATIC ALZHEIMER’S DISEASE (MCI TO MILD DEMENTIA DUE TO AD)

  • Test Drug

    injection

Participate Sites
8Sites

Recruiting8Sites

2021-11-01 - 2031-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2021-07-01 - 2027-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2023-01-01 - 2026-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2023-04-01 - 2030-12-31

Phase III

Active
A PHASE III, MULTICENTER, RANDOMIZED, OPEN LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF INAVOLISIB PLUS FULVESTRANT VERSUS ALPELISIB PLUS FULVESTRANT IN PATIENTS WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE, PIK3CA MUTATED LOCALLY ADVANCED OR METASTATIC BREAST CANCER WHO PROGRESSED DURING OR AFTER CDK4/6 INHIBITOR AND ENDOCRINE COMBINATION THERAPY

  • Condition/Disease

    Patients with locally advanced or metastatic breast cancer who have PIK3CA mutations, are hormone receptor-positive, and HER2-negative

  • Test Drug

    GDC-0077(Inavolisib)Alpelisib(Piqray)Fulvestrant (Faslodex)

Participate Sites
6Sites

Not yet recruiting1Sites

Recruiting5Sites

2020-11-01 - 2027-12-31

Phase III

Active
A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of GDC-9545 Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Patients With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

  • Condition/Disease

    Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

  • Test Drug

    GDC-9545letrozolePalbociclib

Participate Sites
6Sites

Not yet recruiting3Sites

Recruiting3Sites

1 3 4 5 6 7 245
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB